Table 3. Mortality and re-hospitalization rates at three-months and one-year follow-up.
| Characteristics | All | HF categories | Adjusted odds ratio (95% CI) adjusted p-value against reference group |
|||||
|---|---|---|---|---|---|---|---|---|
| HFrEF EF (< 40%) |
HFmrEF EF (40–49%) |
HFpEF EF (≥ 50%) |
p-value | HFrEF EF (< 40%) |
HFmrEF EF (40–49%) |
HFpEF EF (≥ 50%) |
||
| Three-months cumulative mortality (n = 2051) | 143 (7.0) | 86 (7.6) | 31 (6.4) | 26 (5.9) | 0.426 | Ref | 0.86 (0.53–1.40) p = 0.554 |
0.54 (0.31–0.95) p = 0.031 |
| 12-months cumulative mortality (n = 1857) | 197 (10.6) | 108 (11.0) | 47 (11.0) | 42 (10.0) | 0.984 | Ref | 1.07 (0.71–1.60) p = 0.753 |
0.89 (0.56–1.41) p = 0.616 |
| Three-months hospitalization for HF (n = 1906) | 421 (22.1) | 238 (23.0) | 91 (20.0) | 92 (22.0) | 0.520 | Ref | 0.80 (0.60–1.09) p = 0.159 |
0.78 (0.56–1.08) p =0.135 |
| 12-months hospitalization for HF (n = 1633) | 490 (30.0) | 255 (28.0) | 118 (30.0) | 117 (32.0) | 0.335 | Ref | 0.99 (0.74–1.33) p = 0.948 |
1.05 (0.76–1.45) p =0.764 |
HFrEF: Heart failure (HF) with reduced ejection fraction (EF); HFmrEF: HF with mid-range EF; HFpEF: HF with preserved EF; NYHA: New York Heart Association.
Multivariable analyses were conducted using logistic regression models utilizing the simultaneous method. The models were adjusted for age, gender, body mass index, smoking, khat chewing, peripheral vascular disease, hypertension, diabetes mellitus, prior stroke/transient ischemic attack, systolic blood pressure, diastolic blood pressure, serum creatinine, in-hospital percutaneous coronary intervention or coronary artery bypass graft, admission diagnosis, NYHA class, in-hospital course (included non-invasive ventilation, intubation/ventilation, cardiogenic shock, inotropes, intra-aortic balloon pump, acute dialysis/ultrafiltration, atrial fibrillation requiring therapy, major bleeding, blood transfusion, stroke, and systemic infection requiring therapy), discharged medications (diuretics, digoxin, oral nitrates, calcium channel blockers, beta-blockers, aldosterone antagonist, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, aspirin, If channel blocker (ivabradine)).
Data were given as n (%).